At the time of writing, Summit Therapeutics Inc [SMMT] stock is trading at $25.41, up 4.18%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SMMT shares have gain 11.69% over the last week, with a monthly amount drifted -7.09%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on March 26, 2025, when Citigroup upgraded its rating to a Buy and also boosted its price target to $35 from $23. On March 12, 2025, Evercore ISI initiated with a Outperform rating and assigned a price target of $30 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $42 on February 28, 2025. Truist initiated its recommendation with a Buy and recommended $35 as its price target on January 08, 2025. Wells Fargo started tracking with a Overweight rating for this stock on December 11, 2024, and assigned it a price target of $30. In a note dated December 06, 2024, Jefferies initiated an Buy rating and provided a target price of $31 on this stock.
For the past year, the stock price of Summit Therapeutics Inc fluctuated between $2.10 and $36.91. Currently, Wall Street analysts expect the stock to reach $38.25 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $25.41 at the most recent close of the market. An investor can expect a potential return of 50.53% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -0.7 and Total Capital is -0.48. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Summit Therapeutics Inc [NASDAQ:SMMT] has a current ratio of 10.63. As well, the Quick Ratio is 10.63, while the Cash Ratio is 6.06.
